,
“Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial”, PLoS One, vol. 8, p. e74314, 2013.
, “Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers”, PLoS One, vol. 7, p. e33103, 2012.
, , “Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.”, AIDS Res Hum Retroviruses, vol. 13, no. 14, pp. 1163-77, 1997.
, ,